Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. These consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities summarize the latest WHO recommendations on TB and key comorbidities. ...
Fragoulis, George E;
Nikiphorou, Elena;
Dey, Mrinalini;
Zhao, Sizheng Steven;
Courvoisier, Delphine Sophie;
Arnaud, Laurent;
Atzeni, Fabiola;
Behrens, Georg M. N;
Bijlsma, Johannes W. J;
Böhm, Peter;
Constantinou, Costas A;
Garcia-Diaz, Silvia;
Kapetanovic, Meliha Crnkic;
Lauper, Kim;
Luís, Mariana;
Morel, Jacques;
Nagy, György;
Polverino, Eva;
van Rompay, Jef;
Sebastiani, Marco;
Strangfeld, Anja;
Thurah, Annette de;
Galloway, James;
Hyrich, Kimme L.
To develop EULAR recommendations for
screening and prophylaxis of chronic and opportunistic
infections in patients with autoimmune inflammatory
rheumatic diseases (AIIRD).
An international Task Force (TF) (22
members/15 countries) formulated recommendations,
supported by systematic literature review find...
Disease Prevention,
Opportunistic Infections/etiology,
Autoimmune Diseases/complications,
Rheumatic Diseases/complications,
Triage/standards,
Tuberculosis/prevention & control,
Hepatitis B/prevention & control,
Hepatitis C/prevention & control,
Herpesvirus 3, Human,
Pneumocystis carinii/immunology,
Post-Exposure Prophylaxis,
Antiviral Agents/therapeutic use
Tuberculosis (TB) is a leading cause of death from a single infectious agent, despite being largely curable and preventable. In 2019 an estimated 2.9 million of the 10 million people who fell ill with TB were not diagnosed or reported to the World Health Organization. The Political Declaration adopted by...
The political declaration at the first United Nations (UN) high-level meeting on tuberculosis (TB) held
on 26 September 2018 included commitments by Member States to four new global targets.3
One of
these targets is to diagnose and treat 40 million people with TB in the 5-year period 2018–2022. The
ap...
About one fourth of the world’s population is estimated to be infected with the tuberculosis (TB) bacterium, and about 5–10% of those infected develop active TB disease in their lifetime. The risk for active TB disease after infection depends on several factors, the most important being the person’...
Las cepas del bacilo tuberculoso con farmacorresistencia (TB-DR) son más difíciles de tratar que las
farmacosensibles y amenazan el progreso mundial hacia los objetivos establecidos por la Estrategia Fin de
la TB, de la Organización Mundial de la Salud (OMS). Por lo tanto, existe una necesidad imperio...
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services ...
Infection prevention and control consists of evidence-based measures intended to prevent exposure and reduce the risk of transmission of infectious agents.
The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessme...
The World Health Organization’s (WHO’s) strategy for tuberculosis (TB) prevention, care and control for 2015–2035 (known as the End TB Strategy) prioritizes the early diagnosis of TB. This prioritization includes cases of smear-negative disease, which are often associated with coinfection with HIV ...
Isoniazid (H) is one of the most important first-line medicines for the treatment of active
tuberculosis (TB) and latent TB infection (LTBI), with high bactericidal activity and a good safety profile. The emergence of TB strains resistant to isoniazid threaten to reduce the effectiveness of TB treatment....
